PPAR-Gamma Activation May Inhibit the In Vivo Degeneration of Bioprosthetic Aortic and Aortic Valve Grafts under Diabetic Conditions.
Shintaro KatahiraYukiharu SugimuraSophia GruppRobin DoeppJessica Isabel SeligMareike BarthArtur LichtenbergPayam AkhyariPublished in: International journal of molecular sciences (2021)
Under diabetic conditions, pioglitazone leads to elevated circulating levels of adiponectin and to an inhibition of bioprosthetic graft degeneration, including lower expression of chondro-osteogenic genes, decreased media proliferation, and inhibited graft calcification in a small-animal model of DM.
Keyphrases
- aortic valve
- aortic valve replacement
- transcatheter aortic valve replacement
- transcatheter aortic valve implantation
- aortic stenosis
- type diabetes
- wound healing
- insulin resistance
- poor prognosis
- mesenchymal stem cells
- metabolic syndrome
- signaling pathway
- bone marrow
- chronic kidney disease
- genome wide
- fatty acid
- adipose tissue
- coronary artery disease
- long non coding rna
- transcription factor
- glycemic control
- gene expression
- bioinformatics analysis